FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to novel substituted quinolines of general formula (I), where R1 stands for hydroxyC2-6 alkoxy and R2 is H, C1-10alkoxy or hydroxyC1-10alkoxy; R3 is H or F, R4 is H, F, Cl, Br, I or CN; and X is CH or N, or to their stereoisomers, tautomers, or pharmaceutically acceptable salts. Invention also claims pharmaceutical compositions, which include such compounds and methods of applying compounds and compositions in treatment of hyper-proliferative disorders in mammals, especially humans.
EFFECT: claimed compounds inhibit activity of protein- and tyrosinkinase and cell activity, such as proliferation, differentiation, apoptosis, migration and invasion.
15 cl, 3 dwg, 2 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | 2013 |
|
RU2650895C2 |
TWO-SUBSTITUTED PYRAZOLE COMPOUNDS FOR DISEASE TREATMENT | 2017 |
|
RU2772212C2 |
6-ARYL-4-MORPHOLINE-1-YL PYRIDONES SUITABLE FOR TREATMENT OF CANCER OR DIABETES | 2017 |
|
RU2754664C2 |
HETEROAROMATIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE MODULATORS | 2014 |
|
RU2672910C9 |
COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
AZA-ARYL-1-H-PYRAZOL-1-YL-SULPHONAMIDES | 2013 |
|
RU2627268C2 |
MACROCYCLIC PYRIDAZINONE DERIVATIVES | 2014 |
|
RU2660435C2 |
COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2-ADRENERGIC RECEPTOR AGONIST ACTIVITY | 2013 |
|
RU2661877C2 |
ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
PIPERIDINE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2016 |
|
RU2730508C2 |
Authors
Dates
2015-11-20—Published
2012-02-21—Filed